205
Participants
Start Date
October 29, 2012
Primary Completion Date
June 22, 2018
Study Completion Date
June 22, 2018
Valganciclovir
Valganciclovir, 900 mg given orally once daily to all Prophylaxis group subjects for 100 days post transplantation as prophylaxis. Valganciclovir, 900 mg given orally twice daily to Preemptive Therapy group subjects as a PET only after a positive CMV PCR test and stopped after PCR is negative for 2 consecutive weeks.
Ronald Reagan University of California Los Angeles Medical Center, Los Angeles
Emory Clinic - Transplant Center, Atlanta
Mayo Clinic, Rochester - Infectious Diseases, Rochester
Mount Sinai School of Medicine - Medicine - Infectious Diseases, New York
University of Pittsburgh - Medicine - Infectious Diseases, Pittsburgh
University of Washington - Medicine, Seattle
National Institute of Allergy and Infectious Diseases (NIAID)
NIH